Adaptive Biotechnologies Corp
NASDAQ:ADPT
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Price:
3.83 USD
9.43%
Market Closed
Updated:
May 13, 2024
Adaptive Biotechnologies Corp
Cash & Cash Equivalents
|
Adaptive Biotechnologies Corp
Cash & Cash Equivalents Peer Comparison
Comparables:
TMO
DHR
MTD
A
IQV
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
Cash & Cash Equivalents
$71.2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash & Cash Equivalents
$8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
31%
|
CAGR 10-Years
3%
|
|
|
Danaher Corp
NYSE:DHR
|
Cash & Cash Equivalents
$7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash & Cash Equivalents
$70.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash & Cash Equivalents
$1.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
See Also
What is Adaptive Biotechnologies Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
71.2m
USD
71.2m
USD
Based on the financial report for Mar 31, 2024, Adaptive Biotechnologies Corp's Cash & Cash Equivalents amounts to 71.2m USD.
What is Adaptive Biotechnologies Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-9%
-9%
Over the last year, the Cash & Cash Equivalents growth was -25%. The average annual Cash & Cash Equivalents growth rates for Adaptive Biotechnologies Corp have been -26% over the past three years , -9% over the past five years .
You don't have any saved screeners yet
